title: [Enhancing effects of perlecan or vascular endothelial growth factor-165 on angiogenesis in mice].
abstract: OBJECTIVE
  To explore the angiogenesis-promoting effects of perlecan or vascular endothelial growth factor (VEGF) at different time points through quantitative analysis of microvessel density (MVD).
  
  
  METHODS
  Four kinds of scaffolds: open-cell polylactic acid (OPLA) (control), OPLA + VEGF-165, OPLA + perlecan and OPLA + VEGF-165 + perlecan were implanted into mice. At Weeks 1, 2, 3, 4, 6 and 8, OPLA was harvested and then HE and immunocytochemistry were employed to detect the angiogenesis-promoting effects of scaffold. MVD of each group was appraised by the Tukey test.
  
  
  RESULTS
  The scaffolds exhibited excellent biocompatibility with tissue. Numerous vessels were spotted obviously around the implants, especially at Week 8. And the OPLA scaffold degraded with the elapsing of time and its inner part was divided into many sections along with the ingrowth of vessels. Compared with the other three groups, the MVD of the OPLA + VEGF-165 + perlecan group was the highest at all time points. There were statistical differences between the OPLA + VEGF-165 + perlecan and OPLA groups at Week 1 (3.30 ± 0.42 vs 1.80 ± 0.29); MVD of the OPLA + VEGF-165 + perlecan group was thrice as much as the OPLA group at Week 3 (11.70 ± 0.87 vs 4.50 ± 0.34); at Week 8, MVD of the OPLA + VEGF-165 + perlecan group was more than thrice as much as the OPLA group (31.40 ± 1.35 vs 9.90 ± 0.67).
  
  
  CONCLUSIONS
  Angiogenesis is synergistically enhanced by the combined application of VEGF-165 and perlecan in mice.
authors.affiliation: Department of Prosthodontics, Stomatological Hospital, Fourth Military Medical University, Xi'an 710032, China.
authors.forename: Ke
authors.initials: K
authors.lastname: Xu
authors.forename: Li-hui
authors.initials: LH
authors.lastname: Tang
authors.forename: Dan
authors.initials: D
authors.lastname: Wu
authors.forename: Ji-hua
authors.initials: JH
authors.lastname: Chen
mesh_terms: D000818:Animals; D019812:Heparan Sulfate Proteoglycans / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D055806:Microvessels; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D015607:Stents; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology*
chemical_list: D019812:Heparan Sulfate Proteoglycans; D042461:Vascular Endothelial Growth Factor A; C071927:perlecan